EP4377298A1 - Inhibiteurs de sécrétion de protéines - Google Patents

Inhibiteurs de sécrétion de protéines

Info

Publication number
EP4377298A1
EP4377298A1 EP22850498.1A EP22850498A EP4377298A1 EP 4377298 A1 EP4377298 A1 EP 4377298A1 EP 22850498 A EP22850498 A EP 22850498A EP 4377298 A1 EP4377298 A1 EP 4377298A1
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
compound
pharmaceutically acceptable
formula
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22850498.1A
Other languages
German (de)
English (en)
Inventor
Jordi MATA-FINK
Phillip Patrick SHARP
Raman Talwar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gate Bioscience Inc
Original Assignee
Gate Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gate Bioscience Inc filed Critical Gate Bioscience Inc
Publication of EP4377298A1 publication Critical patent/EP4377298A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés utiles dans l'inhibition de la sécrétion de protéines. Les composés de l'invention peuvent être utilisés dans des méthodes de traitement de maladies associées à la sécrétion de protéines, et dans des méthodes d'inhibition de la sécrétion de protéines.
EP22850498.1A 2021-07-27 2022-07-27 Inhibiteurs de sécrétion de protéines Pending EP4377298A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163203621P 2021-07-27 2021-07-27
PCT/US2022/074209 WO2023010051A1 (fr) 2021-07-27 2022-07-27 Inhibiteurs de sécrétion de protéines

Publications (1)

Publication Number Publication Date
EP4377298A1 true EP4377298A1 (fr) 2024-06-05

Family

ID=85088130

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22850498.1A Pending EP4377298A1 (fr) 2021-07-27 2022-07-27 Inhibiteurs de sécrétion de protéines

Country Status (6)

Country Link
EP (1) EP4377298A1 (fr)
CN (1) CN117999256A (fr)
AU (1) AU2022320797A1 (fr)
CA (1) CA3227056A1 (fr)
IL (1) IL310370A (fr)
WO (1) WO2023010051A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070049655A (ko) * 2004-08-13 2007-05-11 제넨테크, 인크. Ａｔｐ-이용 효소 억제 활성을 나타내는2-아미도-티아졸-기재 화합물과 조성물 및 이들의 용도
WO2019046668A1 (fr) * 2017-08-31 2019-03-07 Kezar Life Sciences Thiazoles à substitution amide utilisés en tant qu'inhibiteurs de la sécrétine protéique
BR112021017049A2 (pt) * 2019-02-28 2022-02-08 Kezar Life Sciences Derivados de tiazol como inibidores de secreção de proteínas

Also Published As

Publication number Publication date
CN117999256A (zh) 2024-05-07
IL310370A (en) 2024-03-01
CA3227056A1 (fr) 2023-02-02
WO2023010051A1 (fr) 2023-02-02
AU2022320797A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
CN109071552B (zh) 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法
KR100869616B1 (ko) 프롤린 유도체 및 그의 다이펩티딜 펩티다제－ｉｖ저해제로서의 용도
CN111741769B (zh) 一种多功能化合物、其制备方法及其在医药上的应用
US10106528B2 (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
US11639343B2 (en) Compounds targeting and degrading BCR-ABL protein and its antitumor application
US9029367B2 (en) BACE inhibitors
US11976062B2 (en) Benzisoxazole compound
US11225484B2 (en) Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4
AU2017319430A1 (en) N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
JP2022546717A (ja) Ｕｓｐ３０阻害剤としての活性を有する置換シアノピロリジン類
JPWO2013161851A1 (ja) ベンズアミド誘導体
US10487087B2 (en) Positive allosteric modulators of the GLP-1 receptor
EP3891139A1 (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
US20230100516A1 (en) Pyridazines
US20180362499A1 (en) Soluble epoxide hydrolase inhibitors and uses thereof
EP4377298A1 (fr) Inhibiteurs de sécrétion de protéines
TW202333721A (zh) 作為ＧＬＰ—１受體調節劑之某些八氫呋喃并［３，４—ｂ］吡𠯤
WO2022266368A1 (fr) Inhibiteurs de protéase et leurs méthodes d'utilisation
US11802108B2 (en) Compounds for the modulation of cyclophilins function
CN114206868A (zh) 作为hdac6抑制剂的3-(2-(杂芳基)-吡啶-4-基)-5-(三氟甲基)-1,2,4-噁二唑衍生物
CZ20023773A3 (cs) Amidy (R)-enantiomerů 2-arylpropionových kyselin, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
WO2023185864A1 (fr) Composés pour la dégradation ciblée de kras
KR20080067391A (ko) 베타아미노기를 갖는 1,4-디아제펜 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE